MARATTO

article · Journal of Science and Diseases

COVID-19 infection in two homozygous sickle cell patients in a reference hospital in Cameroon: Case reports

2026Open accessUniversity of Buea

Abstract

We report two cases of COVID-19 infection. The first was a 22-year-old female and the second one a 42-year-old male, were both homozygous sickle cell disease (SCD) patients known since their childhood, but with different medical follow-ups for SCD. Initially, they were admitted to the hospital for a vaso-occlusive crisis. They both subsequently developed respiratory symptoms for which the Initial diagnosis of acute chest syndrome was made. Meanwhile, SARS-COV-2 infection was a potential differential diagnosis due to the prevailing use of COVID-19 pandemic. This infection was subsequently confirmed in these patients, and the common pathophysiological trends described in both conditions were observed, as well as clinical and biological manifestations that could be assimilated to both disease entities. Both patients were managed with the national COVID-19 disease protocol while maintaining specific treatment elements for vaso-occlusive crisis in sickle cell patients. Both had favourable outcomes. In the era of the COVID-19 pandemic, a high index of clinical suspicion of COVID-19 disease is warranted in SCD patients presenting with respiratory symptoms to reduce the morbid mortality of both sickle cell disease and COVID-19.

Research topics

  • Hemoglobinopathies and Related Disorders
  • COVID-19 Clinical Research Studies
  • Blood groups and transfusion

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.64294/jsd.v4i1.264

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.